Biology study for head and neck adenoid cystic carcinoma
Part of Cancer, Ear, nose & throat clinical trials.
This study uses advanced tests on tissue and blood samples to understand why adenoid cystic carcinoma (a type of head and neck cancer) spreads. It aims to find new clues that may help improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with adenoid cystic carcinoma (ACC).
- Your cancer must have started in the head or neck area.
- You must have evidence that the cancer has spread to other parts of your body (metastatic disease).
- You must be willing and able to follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted antibody-drug and focused radiation for people with advanced or recurrent salivary gland cancer that has spread. It aims to see if this treatment can help control the disease when standard treatments have stopped working.
This trial tests a type of high-precision radiation (carbon ions) given to shrink head and neck adenoid cystic carcinoma that cannot be fully removed with surgery. It may help control the tumor while limiting damage to nearby normal tissues.
This study looks at tissue samples from patients who had surgery for head and neck or breast cancer. Researchers want to understand how certain immune cells in the tumor might affect the cancer, which could help improve treatments in the future.
This study looks at tumor samples from people with head and neck cancer to understand why some treatments stop working. By studying the tumor tissue, researchers hope to find better ways to treat this cancer in the future.
This Phase 1/2 study tests how well CB-103 works in people with advanced, hard-to-treat adenoid cystic carcinoma that has a specific NOTCH pathway change. The study also looks at whether combining CB-103 with either lenvatinib or abemaciclib is safe and effective for different groups of patients.
This clinical trial studies an experimental drug called AZD8205 for people with a specific type of advanced adenoid cystic carcinoma (ACC). ACC is a rare cancer that usually starts in the salivary glands. The trial aims to see if the drug can shrink tumors or slow the disease, and it's for those whose cancer has spread or come back and fits certain molecular features.
Hear when a new Adenoid Cystic Carcinoma of the Salivary Gland trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.